Dateline City:
WHITEHOUSE STATION, N.J.
Six oral presentations report MK-3475 monotherapy data across three different tumor types and multiple lines of therapy
Late-breaker presentation of long-term findings of MK-3475 in advanced melanoma, including ipilimumab-nave and treated settings; data included in ASCO Press Program
First presentation of findings evaluating MK-3475 as initial treatment of patients with advanced non-small cell lung cancer
First presentation of findings of MK-3475 in recurrent/metastatic head and neck cancer
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data for the companys investigational
anti-PD-1 antibody, MK-3475, in advanced melanoma, non-small cell lung
cancer (NSCLC), and head and neck cancer, are scheduled to be presented
at the 50th Annual Meeting of the American Society of
Clinical Oncology (ASCO) in Chicago on May 30 June 3, 2014.
Language:
English
Contact:
MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more